In mammalian cells, reactive oxygen species (ROS) are produced via a variety of cellular oxidative processes, including the activity of NADPH oxidases (NOX), the activity of xanthine oxidases, the metabolism of arachidonic acid (AA) by lipoxygenases (LOX) and cyclooxygenases (COX), and the mitochondrial respiratory chain. Although NOX-generated ROS are the best characterized examples of ROS in mammalian cells, ROS are also generated by the oxidative metabolism (e.g., via LOX and COX) of AA that is released from the membrane phospholipids via the activity of cytosolic phospholipase A 2 (cPLA 2 ). Recently, growing evidence suggests that LOX-and COX-generated AA metabolites can induce ROS generation by stimulating NOX and that a potential signaling connection exits between the LOX/COX metabolites and NOX. In this review, we discuss the results of recent studies that report the generation of ROS by LOX metabolites, especially 5-LOX metabolites, via NOX stimulation. In particular, we have focused on the contribution of leukotriene B 4 (LTB 4 ), a potent bioactive eicosanoid that is derived from 5-LOX, and its receptors, BLT1 and BLT2, to NOX stimulation through a signaling mechanism that leads to ROS generation.
INTRODUCTION
Reactive oxygen species (ROS) include highly reactive oxygen radicals [superoxide (O 2 
] and non-radicals that are either oxidizing agents and/or are easily converted into radicals, such as hypochlorous acid (HOCl), ozone (O 3 ), singlet oxygen ( 1 O 2 ), and hydrogen peroxide (H 2 O 2 ) (Bedard et al., 2007) . Although the NADPH oxidase (NOX) family is well recognized as a major source of non-mitochondrial ROS in many cells, including phagocytes and non-phagocytes, arachidonic acid (AA) metabolism by lipoxygenases (LOX) and cyclooxygenases (COX) also plays a role in the generation of ROS in various cell types (Fruehauf et al., 2007; Ostuni et al., 2010) . AA is released from glycerolphospholipids in the nuclear envelope and from the plasma membrane via the activity of cytosolic phospholipase A 2 (cPLA 2 ). AA is subsequently metabolized by LOX and COX to generate a variety of bioactive eicosanoids, including prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs) (as shown schematically in Fig. 1 ) . These enzymes generate ROS as by-products during the oxidation of AA (Yun et al., 2010) . The oxidized metabolites that are generated by LOX or COX induce changes in the intracellular redox balance and have been implicated in the regulation of intracellular signaling events, such as cell proliferation, survival, and migration, and in the progression of the pathogenesis of various human diseases (de Carvalho et al., 2008; Thornber et al., 2009) . Recently, growing evidence indicates that NOX is stimulated by AA metabolites that are generated by COX and LOX. Such evidence suggests a signaling connection between COX/LOX metabolites and NOX. In the present review, we focus on these recent insights into the induced generation of ROS via the AA-metabolite stimulation of NOX.
THE PRODUCTION OF AA METABOLITES BY COX/LOX AND THE STIMULATION OF NOX
COX enzymes catalyze the conversion of AA to prostanoids, including PGs and thromboxane A 2 (TXA 2 ). COXs have three isoforms: the constitutive isoform COX-1, and the inducible isoforms COX-2 and COX-3. In the COX pathway, the first step is the enzymatic conversion of AA to the intermediate prostaglandin G 2 (PGG 2 ). PGG 2 is then reduced to the intermediate prostaglandin H 2 (PGH 2 ) by the peroxidase activity of COX. PGH 2 is sequentially metabolized to prostanoids, including PGs and TXs, by specific synthases (Wang et al., 2010) (Fig. 1) . The PGs exert their biological effects in an autocrine or paracrine manner by binding to the cognate cell surface receptors of the G protein-coupled receptor (GPCR) family. Recently, results from several studies suggest that COX metabolites are capable of stimulating NOX. For example, the 15-deoxy-Delta (12, 14)-prostaglandin J 2 (15d-PGJ 2 )-mediated activation of NOX led to the generation of ROS and to the induction of apoptosis in leukemia and colorectal cancer cells (Shin et al., 2009 ). In addition, 15d-PGJ 2 caused a transient increase in the number of ROS via NOX, which led to an anti-inflammatory effect in murine macrophages (Hong et al., 2008) .
LOX enzymes are classified according to the position of the insertion of oxygen in AA as 5-, 8-, 12-, and 15-LOX. 12-LOX catalyzes the stereo-specific oxygenation of AA to form 12(S)-hydroperoxyeicosatetraenoic acid (HPETE) and 12(S)-hydroxyeicosatetraenoic acid (HETE). Three types of 12-LOX have Fig. 1 . Eicosanoid synthetic pathways. LOXs convert AA into biologically active metabolites such as LTs and HETEs. In the 5-LOX pathway, AA is converted to an intermediary 5-HPETE, which is further metabolized to form the unstable LTA 4 . LTA 4 is subsequently converted to 5-HETE, LTB 4 , LTC 4 , LTD 4 and LTE 4 . In the COX pathway, the first step is the enzymatic conversion of AA to the intermediate PGG 2 , which is then reduced to an intermediate, PGH 2, by the peroxidase activity of COX. PGH 2 is sequentially metabolized to prostanoids, including PGs and TXs, by specific PG and TX synthases.
been well characterized: platelet-type, leukocyte-type, and epidermal-type (Funk et al., 1996) . Although the detailed signaling mechanisms through which 12-LOX stimulates NOX have not yet been established, several reports suggest that 12-LOX acts upstream of the NOX pathways. For example, NOX1 is activated during the spreading of colorectal cancer cells in collagen IV, and this activation is dependent on 12-LOX (de Carvalho et al., 2008) . In addition, 12(S)-HETE stimulation of NOX1 mediates ROS production and migration in colon adenocarcinoma cells .
Two types of 15-LOX have been characterized in humans: reticulocyte-type (15-LOX-1) and epidermal-type (15-LOX-2). 15-LOX-1 is expressed in reticulocytes and eosinophils (Kuhn et al., 1999; Wittwer et al., 2007) , and 15-LOX-2 is expressed in the skin, prostate gland, lungs and cornea (Brash et al., 1997; Krieg et al., 2002) . Linoleic acid (LA) is the preferred substrate for 15-LOX-1. LA is metabolized to 13S-hydroperoxyoctadeca-(9Z, 11E)-dienoic acid (13-HPODE), which is later reduced to 13S-hydroxyoctadeca-(9Z,11E)-dienoic acid (13-HODE). The 15-LOX-2, in contrast, oxygenates AA to 15(S)-HPETE, which is reduced to 15(S)-HETE (Mahipal et al., 2007) . Recently, several papers have reported a correlation between 15-LOX activation and NOX stimulation. For example, the NOX-activation-mediated generation of ROS has been shown to be responsible for the 15-LOX-2 metabolite-induced apoptosis in the chronic myeloid leukemia cell line K-562 (Mahipal et al., 2007) . In addition, the pretreatment of cells with diphenylene iodonium (DPI) inhibited 85% of the ROS production that was induced by 15(S)-HPETE and inhibited 76% of the ROS production that was induced by 15(S)-HETE in Jurkat cells, suggesting that 15-LOX metabolite-induced apoptosis may involve ROS generation through NOX activation (Kumar et al., 2009 The 5-LOX catalyzes the oxygenation of AA at C-5 to form the epoxide intermediate leukotriene A 4 (LTA 4 ). The efficient utilization of endogenous AA by 5-LOX requires a helper protein that is known as 5-LOX-activating protein (FLAP) (PetersGolden et al., 2003) . LTA 4 can then be hydrolyzed by LTA 4 hydrolase to leukotriene B 4 (LTB 4 ) or can be conjugated with glutathione by leukotriene C 4 (LTC 4 ) synthase to yield LTC 4 . Then, LTC 4 can be converted by γ-glutamyl transpeptidase to leukotriene D 4 (LTD 4 ). In turn, LTD 4 is converted to leukotriene E 4 (LTE 4 ) by dipeptidase. LTC 4 , LTD 4 and LTE 4 are known as cysteinyl LTs (cysLTs) and interact with at least two classes of receptors (cysLT1 and cysLT2) (Singh et al., 2010) . Several reports suggest a relationship between the cysLT receptor and ROS generation. For example, pretreatment with cysLT1 receptor antagonists, MK571 or montelukast, have been shown to reduce vascular ROS production, to considerably improve endothelial function, and to ameliorate atherosclerotic plaque generation in vascular smooth muscle cells (VSMC) (Becher et al., 2011) . Indeed, LTC 4 -mediated production of ROS is an essential part of the atherosclerotic response in VSMC following angiotensin (Ang) II stimulation (Mueller et al., 2008) . In addition, LTD 4 mediates proliferative effects through the activation of cysLT1 and subsequent ROS production in airway smooth muscle cells (ASMC) (Fang et al., 2009; Ravasi et al., 2006) . LTB 4 is one of the most potent proinflammatory mediators that promote leukocyte adherence and emigration in addition to increasing vascular protein leakage by acting mainly on leukocytes such as neutrophils and eosinophils (Mackarel et al., 2000; Steiner et al., 2001; Woo et al., 2002) . Previous studies have reported that LTB 4 induces ROS generation in macrophages, neutrophils, eosinophils, and other fibroblasts. In macrophages, LTB 4 activates NOX through the enhanced phosphory- lation and subsequent membrane translocation of p47phox, a cytosolic component of NOX, in a PKC-δ-activation-dependent manner (Serezani et al., 2005a; Woo et al., 2003; Yun et al., 2010) . Similarly, LTB 4 contributes to the activation of p47phox in polyunsaturated fatty acids (PUFA)-stimulated polymorphonuclear leukocytes (Serezani et al., 2005b) . In addition, LTB 4 plays a role in promoting the robust, receptor-mediated activation of NOX in guinea pig eosinophils (Lindsay et al., 1998a; 1998b) . In addition, Woo et al. reported that LTB 4 plays a crucial role in ROS-promoted chemotaxis and proliferation in fibroblasts via the Rac, ERK and cPLA 2 signaling pathways (Woo et al., 2000a; 2000b; .
BLT1/BLT2 AND NOX
Two GPCRs for LTB 4 have been identified, BLT1 and BLT2 (Tager et al., 2003; Yokomizo et al., 1997; . These GPCRs mediate the activities of LTB 4 and function in host immune responses and in the pathogenesis of various inflammatory diseases. The majority of the studies on LTB 4 receptors have focused on the high-affinity receptor, BLT1. The mediatory role of ROS production via BLT1 has been demonstrated using synthetic BLT1 antagonists. For example, the BLT1 receptor antagonist LY293111 inhibits the proliferation of anapla-stic large cell lymphoma (ALCL) cells by arresting the cells in the G1 phase of the cell cycle and by inducing ROS-mediated apoptosis (Zhang et al., 2005) . Reduced phagocytosis has also been observed in human neutrophils that were pretreated with a LTB 4 receptor antagonist (LY292476), implicating LTB 4 in neutrophil phagocytic activity (Tager et al., 2003) . Pretreatment with a BLT1 antagonist (CP105696) has been shown to decrease the phosphorylation and translocation of p47phox in AAstimulated polymorphonuclear leukocytes (Serezani et al., 2005b) . BLT2, a low-affinity LTB 4 receptor, is expressed in a wide variety of tissues (Yokomizo et al., 2000) . Although no clear physiological function has been identified for BLT2, recent reports suggest that BLT2 plays a key role in ROS generation. LTB 4 -induced ROS generation was completely abolished by the inhibition of BLT2 expression in Rat2 fibroblasts (Woo et al., 2000a) . Recently, several reports have demonstrated that BLT2 is critical for NOX upregulation. For example, the induced expression of BLT2 by oncogenic H-Ras results in the generation of ROS via NOX1 upregulation (Choi et al., 2008) . Previous studies have also demonstrated that the LTB 4 -BLT2-NOX1-linked cascade plays a critical role in the invasive and metastatic activity that is associated with oncogenic H-Ras (Choi et al., 2008; Kim et al., 2010a) . In addition, increased ROS generation appears to play an important role in maintaining cancer phenotypes due to the stimulating effects of ROS on cell growth and proliferation (Hu et al., 2005) . Very recently, we demonstrated that NOX1-derived ROS generation is an essential downstream component of the BLT2-mediated pro-survival signaling that protects cells from apoptotic death in estrogen (ER)-negative breast cancer cells (Choi et al., 2010) . Additionally, in aggres-sive bladder cancer cells, BLT2 was shown to promote an invasive, metastatic phenotype by stimulating the NOX1/4-dependent generation of ROS (Kim et al., 2010b) . Ryu et al. demonstrated that the BLT2 pathway is responsible for the upregulation of NOX1 and subsequent ROS generation in response to UVB irradiation. A blockade of BLT2 with the BLT2 inhibitor LY255283 or with siBLT2 attenuated NOX1-mediated ROS production and subsequently reduced the detected apoptotic cell death in HaCaT cells and in primary human keratinocytes (Kim et al., 2010c; Ryu et al., 2010) . The BLT2-mediated NOX1 upregulation-dependent pathway has also been shown to promote the secretion of IL-8 from human mast cells in response to the pro-inflammatory cytokine IL1beta, contributing to angiogenesis (Kim et al., 2010d) . Another study indicated that BLT2-stimulated NOX1 upregulation is a downstream signaling route that mediates the synthesis of Th2 cytokines (IL-4 and IL-13) in antigen-stimulated bone marrowderived mast cells (Cho et al., 2010) . The mechanism through which BLT2 mediates NOX upregulation has not yet been clearly demonstrated. Future studies of the LTB 4 receptors that mediate ROS generation and their relationships to NOX will enhance our understanding of the signaling pathways that are involved in ROS generation.
CONCLUSION
There is a growing body of evidence to suggest that 5-LOXderived ROS are involved in a variety of pathological and inflammatory responses. However, the detailed signaling mechanisms through which LOX metabolites mediate the specific signaling pathways that are involved in ROS generation, especially through NOX upregulation, have yet to be clearly demonstrated. As shown in Fig. 2 , the stimulation of cells through their receptors likely induces the production of ROS by NOX upregulation, and these endogenously produced oxidants have important functions in the regulation of various responses, including chemotaxis, phagocytosis, inflammation response, cancer progression, apoptosis and aging. Further studies are necessary to fully characterize the relationship between eicosanoid receptors and NOX upregulation in terms of ROS signaling.
